Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:CSCI - Post Discussion

COSCIENS Biopharma Inc > Macimorelin and PGX
View:
Post by prophetoffactz on Aug 30, 2024 5:59am

Macimorelin and PGX

Gilles has never mentioned any interest in combining macimorelin with PGX but I was just curious if it was technically desirable what the potential could be.

Perplexity Ai:

Combining macimorelin with PGX technology could potentially lead to several promising applications:

Improved Diagnostic Testing

Enhanced Adult Growth Hormone Deficiency (AGHD) Diagnosis
Macimorelin is currently used to diagnose AGHD. PGX technology could improve its delivery, potentially leading to:
  • Faster absorption and onset of action
  • More precise dosing
  • Improved patient compliance due to easier administration
This could result in more accurate and efficient diagnostic procedures for AGHD.

Therapeutic Applications

Cancer Cachexia Treatment
Macimorelin has been investigated for treating cancer cachexia in early clinical trials. PGX-enhanced delivery could:
  • Increase bioavailability
  • Allow for controlled release formulations
  • Potentially improve efficacy in managing weight loss and muscle wasting in cancer patients
Growth Hormone Disorders
The improved delivery of macimorelin via PGX technology might expand its potential use in treating various growth hormone-related disorders beyond just diagnosis.

Novel Formulations

Combination Therapies
PGX technology offers the possibility of incorporating multiple bioactives into a single dosage form. This could lead to:
  • Combination therapies targeting multiple aspects of growth hormone-related disorders
  • Synergistic formulations enhancing macimorelin's effectiveness
Innovative Delivery Methods
PGX can create thin strips that dissolve instantly on the tongue. For macimorelin, this could mean:
  • Oral thin films for rapid sublingual absorption
  • Improved palatability and ease of use, especially beneficial for pediatric or elderly patients

Expanded Research Opportunities

The unique properties of PGX-processed compounds, such as increased surface area, could open up new avenues for research into macimorelin's mechanisms of action and potential new indications.While these applications show promise, it's important to note that extensive research, development, and clinical trials would be necessary to validate the safety and efficacy of any new macimorelin formulations using PGX technology.
Be the first to comment on this post